Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
Globe Newswire (Thu, 16-Jul 8:30 AM ET)
Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself
Globe Newswire (Thu, 18-Jun 12:42 PM ET)
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Globe Newswire (Tue, 16-Jun 10:30 AM ET)
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Globe Newswire (Tue, 9-Jun 8:30 AM ET)
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
Globe Newswire (Fri, 22-May 11:30 AM ET)
Vericel Raises 2026 Guidance After Record Revenue Growth and Margin Expansion
Market Chameleon (Thu, 7-May 5:13 AM ET)
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Globe Newswire (Thu, 7-May 7:45 AM ET)
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Globe Newswire (Thu, 23-Apr 8:31 AM ET)
Market Chameleon (Thu, 6-Nov 6:24 AM ET)
Vericel Achieves Record Revenue and Profitability in Q3 2025 as MACI Growth Accelerates
Market Chameleon (Thu, 6-Nov 4:12 AM ET)
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Vericel trades on the NASDAQ stock market under the symbol VCEL.
As of July 23, 2026, VCEL stock price climbed to $44.58 with 54,600 million shares trading.
VCEL has a beta of 0.90, meaning it tends to be less sensitive to market movements. VCEL has a correlation of 0.06 to the broad based SPY ETF.
VCEL has a market cap of $2.28 billion. This is considered a Mid Cap stock.
Last quarter Vericel reported $68 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.03.
In the last 3 years, VCEL traded as high as $63.00 and as low as $28.95.
The top ETF exchange traded funds that VCEL belongs to (by Net Assets): IJR, VTI, IWM, XBI, VXF.
VCEL has underperformed the market in the last year with a price return of +17.4% while the SPY ETF gained +18.8%. However, in the short term, VCEL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +29.7% vs +4.3% return in SPY. But in the last 2 weeks, VCEL shares have been beat by the market, returning -5.2% compared to an SPY return of -0.8%.
VCEL support price is $43.38 and resistance is $45.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCEL shares will trade within this expected range on the day.